Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31389276 | 0.86 | ALOX15 (0.58) | ALOX15MAPTTDP1ALDH1A1 | |
| SCHEMBL31389237 | 0.82 | ALOX15 (0.64) | ALOX15 | |
| SCHEMBL2908552 | 0.82 | ALOX15 (0.64) | ALOX15 | |
| SCHEMBL2654259 | 0.81 | GCK (0.51) | ALOX15MAPTTDP1SGMS2P2RY12 | |
| Hydrochloric Acid SCHEMBL28687342 | 0.81 | ALOX15 (0.62) | ALOX15 | |
| SCHEMBL31389285 | 0.81 | ALOX15 (0.70) | ALOX15MAPTALDH1A1P2RY12HSD17B10 | |
| SCHEMBL18528819 | 0.81 | ALOX15 (0.70) | ALOX15MAPTALDH1A1P2RY12HSD17B10 | |
| SCHEMBL4737042 | 0.78 | GRM5 (0.44) | ALOX15MAPTTDP1 | |
| SCHEMBL9378807 | 0.78 | ALOX15 (0.66) | ALOX15MAPTTDP1ALDH1A1P2RY12 | |
| SCHEMBL31389259 | 0.78 | ALOX15 (0.58) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583532-B1 | QUINOLINE DERIVATIVES AS GLUCOKINASE LIGANDS | ASTRAZENECA AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| US-7230108-B2 | Quinoline derivatives as glucokinase ligands | ASTRAZENECA AB (SE) | 2007-06-12 | — | — | US | disclosed |
| US-20060079553-A1 | Quinoline derivatives as glucokinase ligands | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079553-A1 | Quinoline derivatives as glucokinase ligands | GCK, GCKR, GALK1 | ALOX15 3786/4885MAPT 3135/4885TDP1 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.